90111-72-1

Usage

Uses

Used in Pharmaceutical Industry:
5-Cyclohexyl-2H-[1,2,4]triazol-3-ylamine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
5-Cyclohexyl-2H-[1,2,4]triazol-3-ylamine is utilized as a building block in the creation of agrochemicals, specifically for its role in formulating crop protection products that enhance agricultural productivity and crop health.
Used in Antimicrobial Applications:
5-Cyclohexyl-2H-[1,2,4]triazol-3-ylamine is employed as an antifungal and antibacterial agent, leveraging its properties to combat microbial infections and contribute to the control of various pathogens in medical and environmental settings.

InChI:InChI=1/C8H14N4/c9-8-10-7(11-12-8)6-4-2-1-3-5-6/h6H,1-5H2,(H3,9,10,11,12)

Upstream product

• 1937-19-5 1-aminoguanidine hydrochloride 
• 98-89-5 Cyclohexanecarboxylic acid 
• 2719-27-9 cyclohexanylcarbonyl chloride 

Downstream Products

• 1029520-92-0 2-cyclohexyl-5-(2,3-difluorophenylsulfanylmethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 

Relevant academic research and scientific papers

Microscale Parallel Synthesis of Acylated Aminotriazoles Enabling the Development of Factor XIIa and Thrombin Inhibitors

Herein we report a microscale parallel synthetic approach allowing for rapid access to libraries of N-acylated aminotriazoles and screening of their inhibitory activity against factor XIIa (FXIIa) and thrombin, which are targets for antithrombotic drugs. This approach, in combination with post-screening structure optimization, yielded a potent 7 nM inhibitor of FXIIa and a 25 nM thrombin inhibitor; both compounds showed no inhibition of the other tested serine proteases. Selected N-acylated aminotriazoles exhibited anticoagulant properties in vitro influencing the intrinsic blood coagulation pathway, but not extrinsic coagulation. Mechanistic studies of FXIIa inhibition suggested that synthesized N-acylated aminotriazoles are covalent inhibitors of FXIIa. These synthesized compounds may serve as a promising starting point for the development of novel antithrombotic drugs.

Synthesis and evaluation of anti-HIV-1 and anti-HSV-1 activities of 4H-[1,2,4]-triazolo[1,5-a]pyrimidin-5-one derivatives

In a one pot procedure, 18 compounds of 7-(substituted phenyl)-2-substituted-6,7-dihydro-4H-[1,2,4] triazolo [1,5-a] pyrimidin-5-one derivatives (16-33) have been synthesized. 3(5)-Amino-5(3)-substituted-1,2,4-triazole derivatives (7-12) were used as synthones which were cyclocondensed by fusion with substituted methyl cinnamate esters (13-15) to afford the target compounds (16-33). In an effort to develop new non-nucleoside antiviral agents, compounds 16-33 were evaluated for their anti-HIV-1 and anti-HSV-1 activities. Complete inhibition of the proliferation of HIV-1 viruses was achieved by compounds 22, 23 and 24 at concentrations of 25, 25 and 50 μg/ml, respectively. 7-Phenyl-2-(n-pentyl)-6,7-dihydro-4H-[1,2,4]triazolo[1,5-a]pyrimidin-5-one (19) exhibited potential activity against HSV-I with 88% reduction in the viral plaques. The suggested marked specificity of this class of compounds as anti-HIV-1 and HSV-1 agents is discussed.